Relmada Therapeutics
RLMD
79 hedge funds and large institutions have $40.7M invested in Relmada Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 19 closing their positions.
183% more call options, than puts
Call options by funds: $568K | Put options by funds: $201K
2.51% less ownership
Funds ownership: 47.44% → 44.93% (-2.5%)
15% less funds holding
Funds holding: 93 → 79 (-14)
39% less capital invested
Capital invested by funds: $66.5M → $40.7M (-$25.8M)
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
68% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.38M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$859K |
| 3 |
JP Morgan Chase
New York
|
+$639K |
| 4 |
Renaissance Technologies
New York
|
+$195K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$575K |
| 3 |
Goldman Sachs
New York
|
-$550K |
| 4 |
Jane Street
New York
|
-$498K |
| 5 |
GIM
Guild Investment Management
Los Angeles,
California
|
-$425K |
RLMD Hedge Fund Activity: Q2 2024 in Review
79 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2024, worth a combined $40.7M — down 39% from $66.5M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RLMD and 6 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 15 added.
The largest buyer was Franklin Resources, adding an estimated $1.38M. The largest seller was Millennium Management, cutting an estimated $1M.
- 79 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2024, down from 93 in Q1 2024.
- Funds reported $40.7M of Relmada Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
- 6 funds opened new Relmada Therapeutics positions in Q2 2024 and 19 closed out, a net change of -13 holders.
- The largest Relmada Therapeutics buyer in Q2 2024 was Franklin Resources, an estimated $1.38M added.
- The largest Relmada Therapeutics seller in Q2 2024 was Millennium Management, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2024.